Exchange: NASDAQ·Updated 07:30 PM EST
DYN logo

DYN Dyne Therapeutics Inc

$15.50
$0.53
(3.31%)
Today
Closed $15.50
$0.00
(0.00%)
After Hours
Reported EarningsNov 5
Mkt Cap$2.9B
Vol2.23M

About DYN

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
49

Neutral Sentiment

How do you feel about DYN?

Sharelord
$DYN On CAPR forum in ST, which is on fire from Friday, someone mentioned that DYN paid 80k$ for lobbying in April 2026 thus push DYN review based on only 32 patients. Does anybody know if this is true information and have more info on this matter?
parcha
$DYN Dyne Therapeutics to Participate in Upcoming Investor Conference GlobeNewswireNovember 11, 2026 WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conference: Jefferies Global Healthcare Conference, fireside chat on Monday, November 16, 2026 at 2:30 p.m. GMT (9:30 a.m. ET) in London
parcha
$DYN Dyne Therapeutics (NASDAQ: DYN) is expected to report its Q3 2026 earnings on Wednesday, November 4, 2026, after the market closes, with its conference call scheduled for Thursday, November 5, 2026, at 3:00 PM ET.

Advertisement|Remove ads.